key: cord-0726551-vivhn7uu
authors: Tada, Takuya; Zhou, Hao; Samanovic, Marie I.; Dcosta, Belinda M.; Cornelius, Amber; Mulligan, Mark J.; Landau, Nathaniel R.
title: Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
date: 2021-08-06
journal: bioRxiv
DOI: 10.1101/2021.07.19.452771
sha: 90f116b768e5b1c6b9bf30a6e44348aa17efb9a1
doc_id: 726551
cord_uid: vivhn7uu

The increasing prevalence of SARS-CoV-2 variants has raised concerns regarding possible decreases in vaccine efficacy. Here, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses were compared. BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants whereas Ad26.COV2.S-elicited antibodies from a significant fraction of vaccinated individuals were of low neutralizing titer (IC50 <50). The data underscore the importance of surveillance for breakthrough infections that result in severe COVID-19 and suggest the benefit of a second immunization following Ad26.COV2.S to increase protection against the variants.

infectivity and affinity for ACE2. Measurement of the infectivity of the pseudotyped 110 viruses, normalized for particle number, showed that the Lambda variant spike protein 111 increased viral infectivity by 2-fold (Figure 2A) , an increase equivalent to that of the Delta 112

and Delta plus variants. The increase was due to the L452Q mutation and was similar to 113 that of the L452R found in the Delta and Delta plus variants. The other mutations (D246-114 252, G75V-T76I, F490S and T859N) had no significant effect on infectivity (Figure 2A) . 115

Measurement of the relative affinity of the variant spike proteins for ACE2 using sACE2 116 neutralization assay showed that variant spikes had a 3-fold increase in sACE2 binding 117 ( Figure 2B ). This increase was confirmed in a virion:ACE2 binding assay ( Figure 2C) . 118

The increase was caused by the L452R and L452Q mutation and were similar to the 119 increase caused by the N501Y mutation 13, 14 . 120 121 Neutralization by REGN10933 and REGN10987. Analysis of REGN10933 and 122 REGN10987 monoclonal antibodies that constitute the REGN-COV2 therapy showed that 123 REGN10933 had decreased activity against the Beta variant spike which resulted in a 124 127-fold decrease in neutralizing titer. REGN10933 also had decreased activity against 125 the Delta plus variant which resulted in a 92.7-fold decrease in neutralizing titer. The 126 resistance to REGN10933 was attributed to K417N and E484K ( Figure S3 ). REGN10933 127 neutralized virus with the Delta variant spike with a 12-fold decrease in titer which had 128 only a minor effect on the activity of the cocktail. REGN10987 showed a minor reduction 129 in neutralizing titer of virus with the Beta, Delta, Delta plus and Lambda variant spikes but 130 was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

The copyright holder for this preprint (which this version posted July 21, 2021. ; https://doi.org/10.1101/2021.07.19.452771 doi: bioRxiv preprint antibodies 4-11 . The data shown here extend those findings to the Delta plus and Lambda 136 variants. Delta plus and Lambda, VOIs, both displayed a degree of resistance to mRNA 137 vaccine-elicited antibodies similar to that of the Beta and Delta variants. In sera collected 138 ~3 months post-second immunization, BNT162b2 and mRNA-1273 mRNA vaccine-139 elicited antibodies neutralized the variants with a modest 3-fold average decrease in titer 140 resulting in an average IC50 of about 1:600, a titer that is greater than that of convalescent 141 sera and likely, in combination with post-vaccination T-and B-cell memory responses, to 142 provide durable protection. Ad26.COV2.S vaccination-elicited neutralizing antibodies 143

showed a more pronounced decrease in neutralizing titer against the variants, raising the 144 potential for decreased protection against the VOCs and the Lambda variant. Vaccination 145 with Ad26.COV2.S resulted in IC50 titers against Beta, Delta, Delta plus and Lambda 146 variants that decreased 5-7-fold, resulting in mean neutralizing antibody titers of 33, 30, 147 41, and 36 against viruses with the Beta, Delta, Delta plus and Lambda variant spikes, 148 respectively, which according to mathematical modeling, could result in decreased 149 protection against infection 15 . Modeling predicts that 50% protection from infection is 150 provided by a titer that is 20% that of the mean convalescent titer. In this study, given a 151 mean convalescent titer of 346 (Table S1) , 50% protection would correspond to an IC50 152 of 69. The titer required to protect against severe disease was shown to be 3% that of the 153 mean titer of convalescent sera which in this study corresponds to a titer of 10. In a 154 published report of phase 3 trial data, a single dose of Ad26.COV2.S, 28 days post 155 administration, provided 64.0% protection against moderate to severe disease and 81.7% 156 was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. The data presented here emphasize the importance of surveillance for breakthrough 179 infections with the increased prevalence of highly transmissible variants. If an increase in 180 breakthrough infections accompanied by severe COVID-19 is found following adenovirus 181 vector or mRNA vaccination, this would provide a rationale for public health policy-makers 182 and manufacturers to consider booster immunizations that would increase protection 183 against the VOCs and Lambda variant. As such a need is not currently evident, the public 184 health apparatus should focus on primary immunization in the U.S. and globally. The serum was collected at early time point (7 days after second immunization). Each dot 301

represents the IC50 for a single donor. 302 was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Figure S3 . was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine 342 efficacy

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding 344

Neutralizing antibody levels are highly predictive of immune 347 protection from symptomatic SARS-CoV-2 infection

COV2.S elicited neutralizing activity against Delta 350 and other SARS-CoV-2 variants of concern. bioRxiv

Durable Humoral and Cellular Immune Responses Following

S Vaccination for COVID-19. medRxiv, 2021

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2